

08-07-00

A

Please type a plus sign (+) inside this box ☒

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.

JBP-512

First Named Inventor or Application Identifier

Roberts, et al

Express Mail Label No.

EL190926107US

Only for new nonprovisional applications under 37 CFR 1.53(b)

## APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee Transmittal Form (attached hereto in duplicate)
2. ☒ Specification [Total Pages 19]  
(Preferred arrangement set forth below)
  - Descriptive Title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC 113) [Total Sheets ]
4. Oath or Declaration
  - a. ☐ Newly executed (original or copy)
  - b. ☒ Unexecuted original
  - c. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional check boxes 5 and 16)
    - i. ☐ Deletion of Inventor(s)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation by Reference  
(useable if Box 4c is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4c, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Remarks
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

15. ☐ Other:

16. ☒ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:  
Amend the specification by inserting before the first line: -- This is a ☐ Continuation ☐ Divisional  
☒ Continuation-in-Part (CIP) of prior application No.: 09/411,552, filed 10/04/99. --
17. For this divisional application, please cancel original Claims of the prior application before calculating the filing fee.

## 18. CORRESPONDENCE ADDRESS


☐ Customer Number or Bar Code Label or ☒ Correspondence Address below

Name: Audley A. Ciamporcero, Jr., Esq.  
Address: Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003 USA

## 19. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Michele G. Mangini at:  
Telephone: (732) 524-2810 Fax: (732) 524-2808

## 19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Michele G. Mangini	Reg. No. 36806
SIGNATURE		
DATE	August 4, 2000	

<b>FEE TRANSMITTAL</b>	<i>Complete if Known</i>	
	Application Number	N/A; CIP of 09/411,552
	Filing Date	August 4, 2000
	First Named Inventor	Roberts, et al
	Group Art Unit	1615
	Examiner Name	Di Nola Baron, L.
	Attorney Docket Number	JBP-512


### FEE CALCULATION

#### CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE
				\$690.00
TOTAL CLAIMS	8 - 20 =	0	x 18.00	\$ 0.00
INDEPENDENT CLAIMS	2 - 3 =	0	x 78.00	\$ 0.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$260.00	
			TOTAL FEES	\$690.00

### METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/JBP-512/MGM in the amount of \$690.00.  
Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/JBP-512/MGM. Three copies of this sheet are enclosed.

<b>SUBMITTED BY:</b>		<i>Complete (if applicable)</i>
Typed or Printed Name	Michele G. Mangini	Reg. No. 36,806
Signature		Date: August 4, 2000
		<b>Deposit Account No. 10-0750-JBP-512-MGM</b>

DOCKET NO. JBP-51

IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE



Applicant: Roberts, et al

For : Alcohol Free Anti-Bacterial Wipes

Express Mail Certificate

"Express Mail" mailing number: EL190926107US

Date of Deposit: August 4, 2000

I hereby certify that this complete Continuation in Part application, including 19 specification pages with 8 claims and 1 page Abstract, copy of Petition For Extension of Time (1pp), Preliminary Remarks (2pps), Utility Patent Application Transmittal (2pps), and unsigned Declaration and Power of Attorney (4 pps), is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Martin Rizzi

(Typed or printed name of person mailing paper or fee)

A handwritten signature in dark ink, appearing to read "Martin Rizzi", written over a horizontal line.

(Signature of person mailing paper or fee)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Roberts, et al.  
Serial No. : N/A; CIP to 09/411,552 Art Unit: 1615  
Filed : 4 October 1999 Examiner: DiNola-Baron  
For : Alcohol-Free Antibacterial Wipes

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY REMARKS**

Dear Sir:

In response to the Office Action dated 4 April 2000 ("Office Action") in the parent application having United States Serial Number 09/411,552, please consider the following remarks.


**REMARKS**

These preliminary remarks are filed concurrently with the above-referenced continuation-in-part application ("CIP") and in response to the Office Action. The CIP and the Preliminary Remarks are filed in lieu of filing a reply to the Office Action under 37 CFR §1.111 in the parent application no. 09/411,552 filed 4 October 1999. A copy of a one (1) month extension of time to file a response to the Office Action in the parent application, which was filed simultaneously herewith via first class mail, is attached herewith.

Applicants also claim the benefit under Title 35, United States Code §120 of U.S. Application No. 09/411,552 filed 4 October 1999.

Applicants respectfully submit that the rejections in the Office Action are now moot in view of the claims of the CIP in their present form. Applicants further submit that these claims are in condition for allowance. A notice to that effect is earnestly solicited.

Respectfully submitted,

By:   
Michele G. Mangini  
(Attorney for Applicants)  
Reg. No. 36,806  
Dated: 4 August 2000

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2810

- 1 -

## ALCOHOL-FREE ANTI-BACTERIAL WIPES

## CROSS-REFERENCE TO RELATED APPLICATION

5 This Application is a continuation-in-part application of United States Application Number 09/411552 filed on 4 October 1999, which is incorporated herein by reference in its entirety.

## FIELD OF THE INVENTION

10 This invention relates to an alcohol-free anti-bacterial wipe that comprises a cationic antimicrobial agent as its primary active antibacterial agent at a concentration preferably within OTC monograph levels, while maintaining consumer acceptable aesthetics.

## BACKGROUND OF THE INVENTION

15 There are a number of antibacterial wipes on the market and most of them contain high levels of alcohol. Typically, the alcohol acts in two ways, first as an antimicrobial agent, either solely or in combination with other antimicrobial agents, and second as an agent to improve drying time after wiping. However, the use of alcohol has some drawbacks. Particularly,  
20 alcohol dries the skin by removing essential oils and alcohol can be lethal if ingested by infants and small children.

To eliminate problems with alcohol, several non-alcohol containing antibacterial wipes have been developed. However, there are many properties of these wipes upon which could be improved.

25 For example, one potential drawback of alcohol-free wipes is the loss of perceived wet feel of the wipe. Since alcohol reduces surface tension, wipes that contain alcohol will wet the surface of the skin well, thus, giving the user a good perception of wetness. This feeling of wetness has been

identified by consumers as a desirable characteristic for wipes. In order to compensate for the lack of alcohol, alcohol-free wipes must contain some level of surfactant that lowers the surface tension of the aqueous solution, and thereby, improving the wetting of the skin. Although surfactants are effective at lowering surface tension, their use for this purpose has several potential drawbacks that can affect consumer perception. Examples of some of these problems are excessive foaming while wiping and a "tacky" after feel. Thus, the importance of selecting an appropriate surfactant for this use is paramount.

In addition, the choice of antimicrobial agent in an alcohol-free wipe is limited to agents which are soluble in water and are safe and effective. Particularly, when wipes are used on children, the choice of antimicrobial agent must be one which is proven safe and effective for subjects of all ages. There are certain antimicrobial agents which can be used safely in wipe products, such as benzalkonium chloride. However, due to the nature of the wipe fabric, it is often difficult to maintain the concentration of said antimicrobial agents in a wipe at the levels published in the appropriate OTC monograph levels for an antiseptic product. See 21 CFR Parts 333 and 369; Vol. 59, No. 116, June 17, 1994; "Tentative Final Monograph for Health-Care Antiseptic Drug Products; Proposed Rule". The OTC monograph sets levels of 0.10% to 0.13%, ( $\pm$  10%) for benzalkonium chloride in an antiseptic product.

In addition to the aforementioned issues, currently marketed alcohol-free wipes are forced to use fabrics that contain high loads of binder, e.g. about 50 % to about 70% binder with respect to the overall wipe weight. The binder is present to reduce adsorption of the antimicrobial agent to the fabric. Disadvantageously, fabrics possessing large quantities of binders tend to be rather stiff or "boardy", and hence, are not preferred by consumers.

Accordingly, it would be highly desirable to develop an alcohol-free antibacterial wipe which meets the consumer's needs for a wipe that is flexible and has a wet feel. Particularly, it is desirable to produce an alcohol-free wipe that uses a safe and effective antimicrobial agent in a manner which preferably meets the proposed OTC monograph levels of an antimicrobial agent. The unmet need for an alcohol-free antibacterial wipe which is safe and effective for infants, children, and adults while maintaining good consumer aesthetics, is the subject of this invention.

#### SUMMARY OF THE INVENTION

This invention relates to an alcohol-free antibacterial wipe comprising a flexible fabric containing a latex binder, and an aqueous antibacterial solution wherein the aqueous antibacterial solution comprises an effective amount of a cationic antibacterial agent and a sufficient amount of a surfactant and the binder is present in at least about 90% of the substrate thickness.

Further, the invention relates to a method of preparing an alcohol-free antibacterial wipe which comprises

- (i) preparing a solution of a cationic antibacterial agent, a surfactant, and water; and
- (ii) combining said solution with a flexible fabric that is coated with a latex binder, wherein the binder is present in at least about 90% of the substrate thickness.

#### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to an alcohol-free antibacterial wipe comprising a flexible fabric coated with a latex binder and an aqueous antibacterial solution where said aqueous antibacterial solution comprises an effective



amount of a cationic antibacterial agent and a sufficient amount of a surfactant.

As used herein, the term "flexible fabric" refers to a fabric that does not possess a boardy feel to consumers. Flexible fabrics suitable for use in this invention include the non-woven fabrics such as those which contain about 10% to about 100% rayon. In addition, these flexible fabrics may be hydroentangled or air-laided and coated with a binder or extruded and held together with a binder. These flexible fabrics typically have a basis weight of 90 gsm (gram/square meter) to 10 gsm. The preferred flexible fabrics of the invention are about 20% to about 100% rayon. Fabrics which are extruded and held together with a polymer latex binder are particularly preferred. The preferred basis weight for these flexible fabrics is from about 25 gsm to about 40 gsm. The particularly preferred basis weight is about 30 gsm to about 38 gsm. The preferred flexible fabric of the invention is extruded 100% rayon which is held together with a polymer latex binder and has a basis weight of about 30 gsm to about 38 gsm. A commercial example of a desirable fabric is Stearns F- 4575 available from Stearns, Inc. This fabric is coated with a polymer latex binder, E32 Special Latex Binder.

Suitable latex binders for the fabrics include those polymerized from at least one acrylic monomer, and in particular include those binders comprised of, based upon the total weight of binder, a mixture of from about 70% to about 90% of a first self-crosslinking acrylic emulsion polymer, and preferably such a polymer having a Tg of from about 0 °C to about 10 °C and more preferably about 5 °C, and from about 10% to about 30% of a second acrylic emulsion polymer, and preferably such a polymer having a Tg of from about 20 °C to about 40 °C, and more preferably about 34 °C. In one embodiment, the first self-crosslinking acrylic emulsion polymer is non-ionic, and the second acrylic emulsion polymer is anionic. A preferable latex

binder is the "E32 Special Latex Binder," which is comprised of a mixture of about 80% by weight of a self-crosslinking acrylic emulsion polymer latex binder available from the Rohm and Haas Company under the tradename, "RHOPLEX® E32 NP" and about 20% by weight of an acrylic emulsion polymer latex binder available from the Rohm and Haas Company under the tradename, "RHOPLEX® TR407."

The flexible fabric substrates of the present invention typically contain, based upon the total weight of the substrate, from about 25 percent to less than about 40 percent, e.g. from about 25 percent to about 35 percent, of suitable binder.

The phrase "cationic antibacterial agent" refers to quaternary ammonium compounds. Examples of such compounds include but are not limited to benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride and the like, and mixtures thereof. The preferred cationic antibacterial agent is benzalkonium chloride.

"Effective amount," refers to the concentration of cationic antibacterial agent which is present in the aqueous antibacterial solution once said flexible fabric has been combined with said aqueous antibacterial solution. Typically, said cationic antibacterial which are present in the aqueous antibacterial solution at a concentration (weight/weight) of from about 0.05% to about 0.5%, preferably from about 0.15% to about 0.30%, and more preferably from about 0.09% to about 0.15%. The preferred cationic antibacterial agent is benzalkonium chloride and this agent at a concentration of about 0.09% to about 0.15%.

The "surfactants" which are used in this invention are nonionic surfactants, amphoteric surfactants, or mixtures thereof. Examples of amphoteric surfactants include but are not limited to alkylimino-dipropionates, alkylamphoglycinates (mono or di), alkylamphopropionates

(mono or di) alkylamphoacetates (mono or di), N-alkyl  $\beta$ -aminopropionic acids, alkylpolyamino carboxylates and phosphorylated imidazolines. The preferred amphoteric surfactants are disodium lauroamphodiacetate, sodium lauroampho PG-acetate, sodium cocoamphoacetate, and disodium cocamphodipropionate. The particularly preferred amphoteric surfactants are disodium lauroamphodiacetate. One commercial supplier of this material is Mona Industries under the tradename Monateric 949-J. The nonionic surfactants include the fatty alcohol acid or amide ethoxylates, monoglyceride ethoxylates, sorbitan ester ethoxylates, and alkyl polyglycosides. The preferred non-ionic surfactants are PEG-6 caprylic/capric glycerides (available from Croda, Inc., Parsippany, NJ ), polysorbate 20, and PEG-80 sorbitan laurate (available from Uniqema, Wilmington DE). The overall particularly preferred surfactant of the invention is disodium lauroamphodiacetate.

As used herein the phrase "sufficient amount" refers to the amount of surfactant that is necessary to produce a wet feel to the consumer without tackiness. Typically most commercially available surfactants contain an active percentage of the surfactant along with some other components. For purposes of this invention, the term "sufficient amount" refers to the percentage by weight of active amount of the surfactant to the weight of the aqueous composition. When using an amphoteric surfactant, the sufficient amount is typically, based upon the total weight of the solution, from about 0.01% to about 10%, preferably from about 0.05% to 5%, and more preferably, from about 0.10% to about 0.5%. When using a nonionic surfactant, the sufficient amount is typically, from about 0.02% to about 15%, preferably, from about 0.10% to about 10%, and more preferably from about 0.25% to about 2%.

Further, the invention relates to a method of preparing an alcohol-free antibacterial wipe which comprises

- (i) preparing a solution of an cationic antibacterial agent, a surfactant, and water; and
- (ii) combining said solution with a flexible fabric containing a binder such that the binder is present in at least about 90% of the substrate thickness.

The terms "cationic antibacterial agent," "surfactants," and "flexible fabric," have their aforementioned meanings and preferred definitions. Typically the percentage by weight of the cationic antibacterial agent with respect to the weight of said solution is about 0.1% to about 0.5%, more preferably about 0.15% to about 0.3%, more preferably about 0.20% to about 0.23%. Typically the percentage by weight of the surfactant with respect to the weight of said solution is about 0.1% to about 10%, more preferably about 0.5% to about 5%, more preferably about 0.10% to about 1.0%. Typically the percentage by weight of the water with respect to the weight of said solution is about 85% to about 99.5%, more preferably about 90% to about 99%, more preferably about 95% to about 99%.

For example the antibacterial wipes of the invention may be prepared by feeding a flexible fabric into a folding machine. The machine fan folds said flexible fabric into four panels, cutting to a length of six inches and then folding said flexible fabric into thirds. Said flexible fabric comprises 75% pulp, 20% rayon, and 5% polyester/polyethylene where said flexible fabric substrate has a basis weight of 55 gsm and is coated with a latex binder such that the binder is present in at least about 90% and preferably about 100% of the substrate thickness. The appropriately sized flexible fabric is inserted into packet and sealed on three sides, about 4.09 mL of the aqueous antibacterial solution is added to the packet via a piston pump. The

fourth side of the packet is sealed on the fourth side and then dispensed from the machine.

The antibacterial solution may also be applied to the fabric substrate via any other means known in the art such as via spray coating.

5 In one embodiment, the binder is first applied to the substrate in a manner such that it penetrates greater than about 90% and preferably about 100% of the substrate thickness, i.e., not only the front and back substrate surfaces are preferably coated with binder but also the binder is absorbed into the substrate material itself. Then, the antibacterial solution is applied to the coated substrate.

10 In a preferred embodiment, the binder is similarly applied such that it coats the entire front and back surfaces of the substrate and is absorbed into the entire substrate material itself prior to the application of antibacterial solution thereto.

15 We have unexpectedly found that the stability of the antibacterial solution applied to the wipe product of the present invention is greatly improved when the binder penetrates greater than about 90% and preferably about 100% of the substrate thickness.

20 The wipes of the present invention may either be single ply or multi-ply, e.g. two ply substrates laminated to each other via means well known in the art. When removed from its container, the wipes of the present invention are not only sufficiently wet, and thus do not require further wetting in order to activate the antibacterial agent contained therein, but also possess a soft feel to the touch.

25 In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are meant only to suggest a method of practicing the invention. Those knowledgeable in the preparation of wipe products as well as other specialties may find other

methods of practicing the invention. However, those methods are deemed to be within the scope of this invention.

Continued on next page

## EXAMPLES

### Example 1.

#### Preparation of Aqueous Antibacterial Solution A

The ingredients listed in Table A were mixed as follows.

Step 1: Component amounts in this procedure are given in terms of parts by weight to prepare 100 parts of the aqueous antibacterial solution A. 98.8 parts of water are added to the main mix vessel.

Step 2: 0.44 Parts of benzalkonium chloride solution (50%) is weighed in a separate container and then added to the main mixing vessel under agitation and mix well for 10 minutes or until uniform.

Step 3: In a separate container, weigh 0.50 parts of disodium lauroamphodiacetate. In the same container, add 0.06 parts of fragrance. Agitate the disodium lauroamphodiacetate and fragrance mixture until homogenous.

Step 4: Under continuous agitation, add the fragrance and disodium lauroamphodiacetate premix to the main mix vessel and mix well for 10 minutes or until uniform.

Step 5: 0.20 Parts of disodium EDTA is weighed in a separate container and then added to the main mixing vessel under agitation and mix well for 20 minutes or until uniform.

Step 6: If necessary, adjust Ph to 6.0 with 10% citric acid solution.

TABLE A

INCI Name	% Active	% (wt/wt)	% Active (wt/wt)
Disodium Lauroamphodiacetate	30	0.5000	0.1500
Benzalkonium Chloride Solution	50	0.4400	0.2200
Disodium EDTA	30	0.2000	0.0600
Fragrance	100	0.0600	0.0600
Water	0	98.800	0.0000

Example 2

Method of Determining Benzalkonium Chloride Concentration:

The following discussion describes the Benzalkonium Chloride Test Procedure in the expressed solution of this antibacterial wipe. Five wipes are placed into a 30 ml disposable syringe with plunger removed. The plunger is then inserted and pressed to express the liquid from the wipes into a disposable centrifuge tube, pressing hard to collect as much expressed solution as possible. A representative aliquot of the expressed solution is then transferred into an HPLC vial. The concentration of benzalkonium chloride in the expressed solution is determined by the Reverse Phase HPLC (High Performance Liquid Chromatography). The C12, C14 and C16 homologs of benzalkonium chloride are separated from each other and from other components in the expressed solution on a Supelco 25 cm X 4.6 mm, 5 microns Supelcosil LC- CN column and detected by and a Ultraviolet detector at 260 nm. The quantitation is performed by the method of external



standardization compared to a benzalkonium standard solution of approximately at 1.3 to 1.4 mg/ml concentrations. The mobil phase is prepared by adding 650 ml acetonitrile to 350 ml pH 5.0 0.1M Ammonium Acetate Buffer and 1 ml of triethylamine. The injection volume is 25 microliters, flow rate is 1.7 ml/min and the column temperature is 40C.

### Example 3

#### Fabric Selection

Aqueous antibacterial solutions containing a variety of different benzalkonium chloride ("BZK") concentrations were prepared following the general procedure of Example 1. Solution was applied to the fabrics in a quantity equivalent to 350% of the fabric weight as determined by the area and basis weight of the fabric as shown in Table B. The generic term for each fabric is listed with the tradename for each fabric. Each sample was tested when prepared to determine the percentage of benzalkonium chloride ("BZK") present in the prepared product by the procedure of Example 2 (initial) . Subsequently, all samples were stored at 40 °C and were tested over a 13 week period at days 1 through 14 and weeks 3, 4, 8, and 13. The tests were discontinued if the BZK level in the expressed solution was above 0.15% or below 0.09% at any point after seven days from manufacture was above 0.15%. The goal is to prepare a wipe which maintains a BZK level which meets the standard of the OTC monograph, between 0.10% to 0.13%  $\pm$  10% over 13 weeks.

Table B

<u>Fabric . Compositon</u>	<u>Tradename</u>	<u>BZK</u>	<u>Stability Results</u>
Hydroentangled 75% pulp 20% rayon 5% polyester/polyethylene basis wt 55 gsm no binder	Dexter Hydraspun 10180	0.44%	Initial - 0.27% 3w@40°C - 0.108% this experiment was terminated at 3 weeks due to the rapid degradation of BZK
Hydroentangled 65% pulp 30% rayon 5% polyester/polyethylene basis wt 60 gsm no binder	Dexter Hydraspun 10234	0.44%	Initial - 0.12% 3w@40°C - 0.068%
Hydroentangled 55% pulp 40% rayon 5% polyester/polyethylene basis wt 58 gsm with latex binder	Dexter Hydraspun 10444	0.44%	Initial - 0.25% 8days@40°C - 0.118% this experiment was terminated at 8 days due to the rapid degradation of BZK
Hydroentangled 65% rayon, 35% polyester basis wt 55 gsm no binder	Dupont Sontara 8462 Spunlace	0.44%	Initial - 0.39% 7days@40°C - 0.167%
100% rayon basis wt 38 gsm with E358 latex binder	Stearns F-4657	0.20%	Initial - 0.185% 7days@40°C - 0.07%
100% rayon, basis wt 38 gsm with E 32 Special latex binder penetrating through about > 90% of the substrate thickness	Stearns F-4575	0.27%	Initial - 0.102% 13w@40°C - 0.141%

#### Example 4

##### Test to Determine the Appropriate Initial Benzalkonium Chloride Level

The results of Example 3 indicated that the 100% rayon fabric with a basis weight of 38 gms and a special latex binder was the appropriate fabric.

The procedures of examples 1,2, and 3 were repeated on this fabric using different concentrations of BZK in the aqueous antibacterial solution. The fabric and the initial BZK levels are listed in columns 1 and 2 of Table C, respectively. Column 3 lists the initial BZK levels as well as the levels at a particular time period.

Table C

<u>Fabric</u>	<u>BZK Level</u>	<u>Stability Results</u>
100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder penetrating through about > 90% of the substrate thickness	0.27%	Initial – 0.179% 13w@40°C – 0.148%
100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder penetrating through about > 90% of the substrate thickness	0.28%	Initial – 0.183% 13w@40°C – 0.167%

a

100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder	0.33%	Initial – 0.203% 8w@40°C – 0.199%
100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder	0.28%	Initial - 0.153% 8w@40°C – 0.172
100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder	0.25%	Initial – 0.125% 8w@40°C – 0.141%
100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder	0.23%	Initial – 0.102% 4w@40°C – 0.141
100% rayon Stearns F-4575 Basis wt 38 gsm With E 32 Special latex binder	0.23%	Initial – 0.11% 4w@40°C – 0.142%

### Example 5

#### Surfactant Selection

A number of surfactants were tested to determine whether they were suitable for use with alcohol-free antibacterial wipes. The fabric which was

used for all examples was the 100% rayon fabric with a basis weight of 38  
gsm and a polymer latex binder. All products were prepared using an  
aqueous solution with 0.21% benzalkonium chloride. Each final product was  
evaluated by ten (10) consumers to determine whether the wetness and the  
general consistency of the wipes was acceptable. The results of the testing  
along with the surfactant tested (tradenames are in parenthesis) are listed in  
Table D.

Table D

Formula	Surfactant	Consumer Evaluation
8726-092	0.50% PEG-6 Caprylic/Capric Glycrides (Glycerox 767)	Unacceptable – tacky afterfeel
8726-101	0.30% PEG-6 Caprylic/Capric Glycrides (Glycerox 767)	Unacceptable – tacky afterfeel
8726-102	0.15% PEG-6 Caprylic/Capric Glycrides (Glycerox 767)	Unacceptable – tacky afterfeel
8726-112	0.50% Disodium Lauroamphodiacetate (Monateric 949J)	Acceptable – superior afterfeel, low foam
8726-114	0.10% Cocamidopropylamine Oxide (Ammonyx CDO)	Unacceptable – too much foam, poor afterfeel

What is claimed is:

1. An alcohol-free antibacterial wipe comprising:  
a flexible fabric substrate containing a latex binder; and  
an aqueous antibacterial solution,  
wherein said aqueous antibacterial solution is comprised of an  
effective amount of a cationic antibacterial agent and a sufficient  
amount of a surfactant and said binder is present in at least about  
90% of the substrate thickness.
2. The wipe of claim 1 wherein the substrate is further comprised of a  
front surface and a back surface, and said binder is present on both of  
the surfaces.
3. The alcohol-free antibacterial wipe of claim 1 wherein  
said flexible fabric substrate is comprised of rayon,  
said cationic antibacterial agent is benzalkonium chloride, and  
said surfactant is disodium lauroamphodiacetate.
4. The alcohol-free antibacterial wipe of claim 2 wherein the effective  
amount of benzalkonium chloride is, based upon the total weight of  
the aqueous antibacterial solution, from about 0.09% to about 0.15%.
5. The wipe of claim 1 wherein the binder is a polymer latex polymerized  
from at least one acrylic monomer.

6. The wipe of claim 1 wherein the binder is a polymer latex comprised of a mixture of a self-crosslinking acrylic emulsion polymer latex binder and an acrylic emulsion polymer latex binder.

5

7. A method of preparing an alcohol-free antibacterial wipe which comprises

(i) preparing a solution of an cationic antibacterial agent, a surfactant, and water; and

(ii) applying said solution onto a flexible fabric substrate containing a latex binder, wherein said binder is present in at least about 90% of the substrate thickness.

10

8. The method of claim 7 which further comprises

(i) preparing a solution of, based upon the total weight of the solution, from about 0.21% to about 0.22% benzalkonium chloride, about 0.15% to about 0.3% disodium lauroamphodiacetate, and water; and

(ii) applying said solution onto a substrate comprised of rayon and containing a latex binder, wherein said binder is present in at least about 90% of the substrate thickness.

15

20

continued on next page

5

JBP470cip3.doc



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Alcohol-Free Antibacterial Wipes, the specification of which

(check one) ☐ is attached hereto.

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and was amended on \_\_\_\_\_.  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119	
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09/411,552  
Application Serial No.

4 October, 1999  
Filing Date

Pending  
Status

\_\_\_\_\_  
Application Serial No.

\_\_\_\_\_  
Filing Date

\_\_\_\_\_  
Status

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith as well as to file equivalent patent applications in countries foreign to the United States including the filing of international patent applications in accordance with the Patent Cooperation Treaty: Audley A. Ciamporzero, Jr. (Reg. #26,051), Steven P. Berman (Reg. #24,772), Andrea L. Colby (Reg. #30,194), Michael Stark (Reg. #32,495), and Michele G. Mangini (Reg. #36,806) One Johnson & Johnson Plaza, New Brunswick, NJ 08933.

Address all telephone calls to Michele G. Mangini at telephone no. (732) 524-2810.

Address all correspondence to Audley A. Ciamporzero, Jr., One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's Signature: \_\_\_\_\_

Full Name of Sole  
or First Inventor

Joseph T. Roberts

Date: \_\_\_\_\_

Citizenship: USA

Residence: 1 Baltic Street, Edison, New Jersey 08817

Post Office Address: Same as above

Inventor's Signature: \_\_\_\_\_

Full Name of Second Joint  
Inventor, If Any

Carol A. Duden-Antenna

Date: \_\_\_\_\_

Citizenship: USA

Residence: 94 Swan Street, Lambertville, New Jersey 08530

Post Office Address: Same as above

Inventor's Signature: \_\_\_\_\_

Full Name of Third Joint  
Inventor, If Any

Shaw Kong Chang

Date: \_\_\_\_\_

Citizenship:

Residence: 56 Michelle Lane, Belle Mead, New Jersey 08502

Post Office Address: Same as above

004030 "263030"

Walter J. Hines

Date:

Post Office Address: Same as above

Joseph Librizzi

Date:

Post Office Address: Same as above

[illegible]